Thursday, February 02, 2012

How the New Role of the CRO Affects Patient Enrollment

Thought Leader: Richard Malcolm, CEO, Acurian

In this episode, Dr. Malcolm discusses how the role of the CRO is transitioning from commodity service supplier to strategic partner, and the unintended negative consequences this could have on what is already the most expensive part of clinical trials: patient enrollment.

Play Podcast

For more information on how you can be featured in a podcast, contact Dan Limbach at or call him at (847) 594-0157.

No comments: